Brind.

Mirum Pharmaceuticals developed treatments for rare diseases in July 2025.

1 report, 1 independent Updated Jul 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Mirum Pharmaceuticals

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Mirum Pharmaceuticals
biopharmaceutical company
- Trump's pledge to unleash oil and gas benefits stocks, specifically impacting Mirum Pharmaceuticals.Sun 07:23

Related events

Mirum Pharmaceuticals trades on the Nasdaq exchange.Jun 19

Coverage

Newest first; wire copies grouped

Jul 11Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., July 10, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced th